OICHARTS
8 AMThe 8 AM report →

PMVP

PMV Pharmaceuticals, Inc · XNAS · 131 sessions on record
$1.67▲ +0.24 · +16.8%from $1.43 the session before · Sep 30, 2026 close · end of day
Open
$1.44
High
$1.73
Low
$1.44
Day's range
$0.2920% of the previous close
VWAP
$1.64close +2.0% from it
Volume, shares
3.13M3.33× the 20-session average
Traded, $
$5.1M
Trades
10.6K290 shares per trade
Previous close
$1.43+0.24 to the close
Market cap
$89.3Mat the close of Sep 30
Day range81% of the way up
$1.44$1.73
52-week range92% of the way up
$1.04 Jun 11$1.73 Sep 30

−3.2% from the high · +61% from the low

Options

No listed options on PMVP

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
PMVP close over the last 126 sessions, with S&P 500 rebased to the first close1.051.592.13axis spans 103%S&P 500PMVPApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 103 percent.

Quarterly results

consolidated · latest filed Aug 14, 2026 · SEC filings

Profit −$18.1M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of PMVP on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 14——−$18.1M—-0.34▼ −0.8%S&P 500 −0.5% · −0.3 pp
Mar 2026filed Aug 14——−$18.0M—-0.34▼ −0.8%S&P 500 −0.5% · −0.3 pp
Dec 2025filed Mar 6——−$18.0M—-0.33—not reached
Sep 2025filed Nov 12——−$21.1M—-0.40—not reached
Jun 2025filed Aug 14——−$21.2M—-0.41▼ −0.8%S&P 500 −0.5% · −0.3 pp
Mar 2025filed Aug 14——−$17.4M—-0.34▼ −0.8%S&P 500 −0.5% · −0.3 pp
Dec 2024filed Mar 3——−$23.0M—-0.45—not reached
Sep 2024filed Nov 12——−$19.2M—-0.37—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of PMVP on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025——−$77.7M—-1.48
FY24to Dec 2024——−$58.7M—-1.14
FY23to Dec 2023——−$69.0M—-1.44
FY22to Dec 2022——−$73.3M—-1.61
FY21to Dec 2021——−$57.8M—-1.28

Fundamentals

consolidated · filings to Jun 2026 · close $1.67 on Sep 30

1.3 times book value, market cap $89.3M.

Valuation
Market cap
$89.3Mon Sep 30
Price to earnings
—
Trailing EPS
$-1.41diluted · consolidated · four quarters to Jun 2026
Price to book
1.3consolidated · balance sheet to Jun 2026
Book value a share
$1.34consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-71%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
53.5Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$75.2Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—

Corporate actions

exchange records

No corporate action on record for PMVP yet.

Price history

131 sessions on record · to Sep 30 · end of day

PMVP is +29.5% over 20 sessions against the S&P 500's +0.1%, 3.2% below its 52-week high, realised volatility 84% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $PMVP %S&P 500 %Difference pp
120 sessionssince Apr 9$1.33▲ +26%▲ +12%+13
60 sessionssince Jul 7$1.24▲ +35%▲ +2.0%+33
20 sessionssince Sep 1$1.29▲ +29%▲ +0.11%+29
5 sessionssince Sep 23$1.37▲ +22%▼ −0.67%+23
1 sessionsince Sep 29$1.43▲ +17%▼ −0.21%+17
Averages of the closeclose against each average
5-session average
$1.43close +17% from it
20-session average
$1.40close +19% from it
50-session average
$1.30close +28% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.126.9% of the close
Average day's range, 20
$0.137.5% of the close
Volume against 20 sessions
3.33×3.13M vs 753K average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
84%≈ ±5.3% a session · moved more than that on 3 of 20
Realised volatility, 60
69%≈ ±4.4% a session · moved more than that on 17 of 60
Beta to S&P 500, 60
-0.11moved with S&P 500 on 21 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
12 up · 8 downof 20
Last 60 sessions
31 up · 25 downof 56
Best session, 250
▲ +17%Sep 30
Worst session, 250
▼ −9.3%Sep 23

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 25% of reported volume on Sep 30, 2026, against 36% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
PMVP daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 2026369K1.5M24.7%
Sep 29, 2026149K267K55.8%
Sep 28, 202640.8K90.5K45.1%
Sep 25, 202647K95.9K49.0%
Sep 24, 202687.4K214K40.8%
Sep 23, 202674.3K265K28.1%
Sep 22, 202628.7K146K19.7%
Sep 21, 202698.6K146K67.7%
Sep 18, 202666.9K337K19.8%
Sep 17, 202650.9K153K33.3%

Filings

SEC EDGAR · newest first
PMVP SEC filings
FiledFormReport date
Sep 15, 2026SCHEDULE 13G—
Sep 2, 20268-KAug 31, 2026
Sep 2, 2026424B5—
Aug 31, 2026424B3—
Aug 31, 2026424B5—
Aug 31, 20268-KAug 31, 2026
Aug 14, 202610-QJun 30, 2026
Aug 14, 20268-KAug 14, 2026
Jul 28, 2026SCHEDULE 13G/A—
Jul 10, 2026SCHEDULE 13G/A—
Jun 5, 20264Jun 4, 2026
Jun 5, 20264Jun 4, 2026
Jun 5, 20264Jun 4, 2026
Jun 5, 20264Jun 4, 2026
Jun 5, 20268-KJun 4, 2026
Jun 5, 20264Jun 4, 2026
May 15, 2026SCHEDULE 13G/A—
May 12, 202610-QMar 31, 2026
May 12, 20268-KMay 12, 2026
May 4, 2026SCHEDULE 13G/A—
Apr 22, 2026ARSDec 31, 2025
Apr 22, 2026DEFA14A—
Apr 22, 2026DEF 14AJun 4, 2026
Mar 9, 20264Mar 5, 2026
Mar 9, 20264Mar 5, 2026

About PMV Pharmaceuticals, Inc

SEC and exchange records
Company
PMV Pharmaceuticals, Inc
Exchange
XNAS
SEC CIK
1699382
Sessions on record
131
Price source
End of day · delayed
Computed
2 Oct, 01:43 am IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.